Marshall Wace LLP Sells 607,297 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Marshall Wace LLP cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 70.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 253,637 shares of the biopharmaceutical company's stock after selling 607,297 shares during the quarter. Marshall Wace LLP owned approximately 0.21% of Catalyst Pharmaceuticals worth $5,293,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. JPMorgan Chase & Co. boosted its holdings in Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after buying an additional 33,888 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock worth $8,710,000 after acquiring an additional 50,888 shares during the period. Redhawk Wealth Advisors Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $1,273,000. Finally, Spire Wealth Management raised its stake in shares of Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 13,429 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded up $0.26 during mid-day trading on Friday, reaching $23.45. The stock had a trading volume of 612,029 shares, compared to its average volume of 1,108,879. The stock has a market capitalization of $2.86 billion, a P/E ratio of 19.87, a P/E/G ratio of 3.31 and a beta of 0.79. The firm has a 50 day moving average price of $22.58 and a two-hundred day moving average price of $22.20. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

Analysts Set New Price Targets

Several research analysts have commented on the company. Bank of America restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.29.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.